256 related articles for article (PubMed ID: 24795896)
21. Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function.
Rigg RA; Aslan JE; Healy LD; Wallisch M; Thierheimer ML; Loren CP; Pang J; Hinds MT; Gruber A; McCarty OJ
Am J Physiol Cell Physiol; 2016 Mar; 310(5):C373-80. PubMed ID: 26659727
[TBL] [Abstract][Full Text] [Related]
22. Targeting Bruton's tyrosine kinase in B cell malignancies.
Hendriks RW; Yuvaraj S; Kil LP
Nat Rev Cancer; 2014 Apr; 14(4):219-32. PubMed ID: 24658273
[TBL] [Abstract][Full Text] [Related]
23. Dual functions of Bruton's tyrosine kinase and Tec kinase during Fcgamma receptor-induced signaling and phagocytosis.
Jongstra-Bilen J; Puig Cano A; Hasija M; Xiao H; Smith CI; Cybulsky MI
J Immunol; 2008 Jul; 181(1):288-98. PubMed ID: 18566394
[TBL] [Abstract][Full Text] [Related]
24. Suppression of glomerulonephritis in lupus-prone NZB × NZW mice by RN486, a selective inhibitor of Bruton's tyrosine kinase.
Mina-Osorio P; LaStant J; Keirstead N; Whittard T; Ayala J; Stefanova S; Garrido R; Dimaano N; Hilton H; Giron M; Lau KY; Hang J; Postelnek J; Kim Y; Min S; Patel A; Woods J; Ramanujam M; DeMartino J; Narula S; Xu D
Arthritis Rheum; 2013 Sep; 65(9):2380-91. PubMed ID: 23754328
[TBL] [Abstract][Full Text] [Related]
25. Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model.
Pamuk ON; Can G; Ayvaz S; Karaca T; Pamuk GE; Demirtas S; Tsokos GC
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S15-22. PubMed ID: 26148346
[TBL] [Abstract][Full Text] [Related]
26. [Syk inhibitors].
Kimura Y; Chihara K; Takeuchi K; Sada K
Nihon Rinsho; 2013 Jul; 71(7):1248-52. PubMed ID: 23961675
[TBL] [Abstract][Full Text] [Related]
27. Spleen tyrosine kinase promotes acute neutrophil-mediated glomerular injury via activation of JNK and p38 MAPK in rat nephrotoxic serum nephritis.
Ryan J; Ma FY; Kanellis J; Delgado M; Blease K; Nikolic-Paterson DJ
Lab Invest; 2011 Dec; 91(12):1727-38. PubMed ID: 21894146
[TBL] [Abstract][Full Text] [Related]
28. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
Robak T; Robak P
Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
[TBL] [Abstract][Full Text] [Related]
29. Generation of a novel system for studying spleen tyrosine kinase function in macrophages and B cells.
Miller AL; Zhang C; Shokat KM; Lowell CA
J Immunol; 2009 Jan; 182(2):988-98. PubMed ID: 19124742
[TBL] [Abstract][Full Text] [Related]
30. Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials.
Rozkiewicz D; Hermanowicz JM; Kwiatkowska I; Krupa A; Pawlak D
Molecules; 2023 Mar; 28(5):. PubMed ID: 36903645
[TBL] [Abstract][Full Text] [Related]
31. Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis.
Rankin AL; Seth N; Keegan S; Andreyeva T; Cook TA; Edmonds J; Mathialagan N; Benson MJ; Syed J; Zhan Y; Benoit SE; Miyashiro JS; Wood N; Mohan S; Peeva E; Ramaiah SK; Messing D; Homer BL; Dunussi-Joannopoulos K; Nickerson-Nutter CL; Schnute ME; Douhan J
J Immunol; 2013 Nov; 191(9):4540-50. PubMed ID: 24068666
[TBL] [Abstract][Full Text] [Related]
32. Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders.
Robak T; Robak E
Expert Opin Investig Drugs; 2012 Jul; 21(7):921-47. PubMed ID: 22612424
[TBL] [Abstract][Full Text] [Related]
33. Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia.
Wu H; Hu C; Wang A; Weisberg EL; Chen Y; Yun CH; Wang W; Liu Y; Liu X; Tian B; Wang J; Zhao Z; Liang Y; Li B; Wang L; Wang B; Chen C; Buhrlage SJ; Qi Z; Zou F; Nonami A; Li Y; Fernandes SM; Adamia S; Stone RM; Galinsky IA; Wang X; Yang G; Griffin JD; Brown JR; Eck MJ; Liu J; Gray NS; Liu Q
Leukemia; 2016 Jan; 30(1):173-81. PubMed ID: 26165234
[TBL] [Abstract][Full Text] [Related]
34. Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 - 2013.
Norman P
Expert Opin Ther Pat; 2014 May; 24(5):573-95. PubMed ID: 24555683
[TBL] [Abstract][Full Text] [Related]
35. Genetic evidence for a tyrosine kinase cascade preceding the mitogen-activated protein kinase cascade in vertebrate G protein signaling.
Wan Y; Bence K; Hata A; Kurosaki T; Veillette A; Huang XY
J Biol Chem; 1997 Jul; 272(27):17209-15. PubMed ID: 9202044
[TBL] [Abstract][Full Text] [Related]
36. Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: a review.
Kaur M; Singh M; Silakari O
Eur J Med Chem; 2013 Sep; 67():434-46. PubMed ID: 23917087
[TBL] [Abstract][Full Text] [Related]
37. Getting Syk: spleen tyrosine kinase as a therapeutic target.
Geahlen RL
Trends Pharmacol Sci; 2014 Aug; 35(8):414-22. PubMed ID: 24975478
[TBL] [Abstract][Full Text] [Related]
38. Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
Zhang Z; Zhang D; Liu Y; Yang D; Ran F; Wang ML; Zhao G
Arch Pharm (Weinheim); 2018 Jul; 351(7):e1700369. PubMed ID: 29741794
[TBL] [Abstract][Full Text] [Related]
39. A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis.
Smith J; McDaid JP; Bhangal G; Chawanasuntorapoj R; Masuda ES; Cook HT; Pusey CD; Tam FW
J Am Soc Nephrol; 2010 Feb; 21(2):231-6. PubMed ID: 19959716
[TBL] [Abstract][Full Text] [Related]
40. Novel small molecule therapeutics in rheumatoid arthritis.
Kelly V; Genovese M
Rheumatology (Oxford); 2013 Jul; 52(7):1155-62. PubMed ID: 23297340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
